Livforsakringsbolaget Skandia, Omsesidigt Harmony Biosciences Holdings, Inc. Transaction History
Livforsakringsbolaget Skandia, Omsesidigt
- $1.72 Billion
- Q3 2024
A detailed history of Livforsakringsbolaget Skandia, Omsesidigt transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Livforsakringsbolaget Skandia, Omsesidigt holds 44,900 shares of HRMY stock, worth $1.86 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
44,900
Previous 24,300
84.77%
Holding current value
$1.86 Million
Previous $733,000
144.61%
% of portfolio
0.1%
Previous 0.06%
Shares
3 transactions
Others Institutions Holding HRMY
# of Institutions
224Shares Held
45.1MCall Options Held
48.2KPut Options Held
56.5K-
Valor Management LLC Chicago, IL11.2MShares$465 Million100.0% of portfolio
-
Black Rock Inc. New York, NY5.84MShares$242 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.52MShares$146 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA2.61MShares$108 Million11.62% of portfolio
-
Pacer Advisors, Inc. Malvern, PA2.51MShares$104 Million0.19% of portfolio
About Harmony Biosciences Holdings, Inc.
- Ticker HRMY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,161,400
- Market Cap $2.45B
- Description
- Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...